Myocardial Infarction in the Elderly

February 28, 2025 updated by: Ryazan State Medical University

Hospital Registry of Patients with Myocardial Infarction in Individuals Aged 75 Years and Older

An observational registry study of patients aged 75 years and older with an established diagnosis of myocardial infarction, initiated in 2020, with an assessment of clinical, instrumental, demographic and prognostic data. Statistical analysis was performed using the StatTech v. 4.5.0 program (developer - StatTech LLC, Russia). Differences were considered statistically significant at p <0.05.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Professor Pereverzeva, Doctor of Medical Sciences
  • Phone Number: +79209945558
  • Email: pereverzevakg@gmail.com

Study Locations

  • Russian Federation
      • Ryazan, Russian Federation, 390026
        • Recruiting
        • State Budgetary Institution of the Ryazan Region "Regional Clinical Cardiology Dispensary"
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

patients hospitalized in the State Budgetary Institution of the Ryazan Region "Regional Clinical Cardiology Dispensary" with an established diagnosis of myocardial infarction

Description

Inclusion Criteria:

- age 75 years and older, presence of an established diagnosis of myocardial infarction at the time of hospitalization.

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
all-cause death, myocardial infarction, stroke, unplanned percutaneous coronary
Time Frame: 10 years
10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ryazan State Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2020

Primary Completion (Estimated)

September 1, 2028

Study Completion (Estimated)

December 1, 2030

Study Registration Dates

First Submitted

February 28, 2025

First Submitted That Met QC Criteria

February 28, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 28, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 0922142025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myocardial Infarction (MI)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe